Opioid-induced Constipation Clinical Trial
Official title:
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo Controlled Phase 2 Study of Once-Daily Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures
The purpose of this study is to examine the safety and activity of MNTX in relieving opioid-induced constipation following orthopedic procedures.
This is a double-blind, randomized, parallel-group, placebo- controlled Phase 2 study to evaluate the safety and activity of subcutaneous (SC) MNTX versus SC placebo in participants who have undergone orthopedic procedures and who are expected to require opioids for 1 week after randomization. Participants will sign an informed consent form and be screened between Days 4-10 after their orthopedic procedure. Those participants who meet all eligibility requirements will be enrolled in the study. Treatment with study medication will be continued until either the participant no longer requires opioid medication for pain relief or the maximum number of doses is reached. Originally, participants were receiving treatment for up to 7 days. Then after Protocol Amendment 1 (12 March 2008), the duration of treatment changed from "up to 7 days" to "up to 4 days". ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01965652 -
Long Term Safety of Naldemedine
|
Phase 3 | |
Completed |
NCT04173858 -
Evaluation of the Quality of Life of Patients With Opioid-induced Constipation Under Treatment With Naloxegol
|
||
Recruiting |
NCT05149833 -
European Study of Opioid Induced Constipation
|
||
Completed |
NCT01186770 -
A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain
|
Phase 3 | |
Completed |
NCT02270983 -
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
|
Phase 2 | |
Terminated |
NCT01696643 -
Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
|
Phase 3 | |
Completed |
NCT01993940 -
Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation
|
Phase 3 | |
Terminated |
NCT00399659 -
Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.
|
Phase 3 | |
Terminated |
NCT01901302 -
Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
|
Phase 3 | |
Withdrawn |
NCT00858754 -
Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects
|
Phase 4 | |
Completed |
NCT05770960 -
Colonic Motor Patterns in Healthy Volunteers
|
Phase 4 | |
Terminated |
NCT01384292 -
Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain
|
Phase 3 | |
Completed |
NCT00672477 -
Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness
|
Phase 4 | |
Recruiting |
NCT03687268 -
Naloxone HCl PR Tablets in Patients With Opioid Induced Constipation
|
Phase 3 | |
Completed |
NCT00672139 -
Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness
|
Phase 4 | |
Terminated |
NCT01901341 -
The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
|
Phase 3 | |
Recruiting |
NCT03720613 -
Risk of Major Adverse Cardiovascular Events for Naldemedine and Other Medications for Opioid Induced Constipation in Adults With Chronic Non-Cancer Pain
|
||
Completed |
NCT01368562 -
Compassionate Use Study of Methylnaltrexone
|
N/A | |
Completed |
NCT01040637 -
A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation
|
Phase 1/Phase 2 | |
Recruiting |
NCT05133076 -
Safety and Preliminary Efficacy of BGP345A in Constipation Due to Opioid-based Medications
|
Phase 2 |